Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation

BACKGROUND: Andexanet alfa (andexanet) is a modified human factor Xa (FXa) approved for anticoagulation reversal in patients with life‐threatening bleeding treated with rivaroxaban or apixaban. Four‐factor prothrombin complex concentrates (4F‐PCCs) are approved for reversal of vitamin K antagonist–i...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Genmin, Lin, Joyce, Bui, Khanh, Curnutte, John T., Conley, Pamela B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles ‐ Thrombosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695565/
https://www.ncbi.nlm.nih.gov/pubmed/33313467
http://dx.doi.org/10.1002/rth2.12418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695565/
https://www.ncbi.nlm.nih.gov/pubmed/33313467
http://dx.doi.org/10.1002/rth2.12418

Ejemplares similares